daytraders after market lounge 2nd Oct, page-31

The exciting part is that it is a Worlds first and has been validated with clinical trials.

'the world's first clinically-tested, regulatory Approved smartphone application for respiratory disease diagnosis and management.'

This is ISN and ALT all over again but the big advantage it will have over those two is the fact that it doesn't require any additional hardware.

ISN required the wheezeometer, ALT required the pericoach.

NLS only requires what we already have, a smartphone.

'ResApp's technology is unique in that it does not require the purchase or use of additional hardware. Only the patients smartphone is needed.'